DCTH recently revised and narrowed the focus of their request for chemosaturation procedure to ocular melanoma with liver mets from metastatic melanoma of any source at urging of FDA. This seems to be an effort by agency to assist the company with gaining approval this go around. Chemosaturation once approved will likely see significant use in off-label indications.